Inhibition of central nervous system effects from smoking and sensory effects from smoking
AssigneePhilip Morris USA Inc.
InventorsGerd Kobal, Justin Heynekamp, Peter Reeh, Munmaya K. Mishra
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions and methods of use therefor for reducing the desire to engage in smoking are disclosed. More specifically, the pharmaceutical composition utilizes an active ingredient to reduce the side effects of smoking cessation and to limit the molecular feedback caused by nicotine-mediated activation of acetylcholine receptors.
Claims26
A product for reducing an individual's desire to engage in smoking, wherein the product comprises:
- an effective amount of an active ingredient comprising at least one compound selected from the group consisting of camphor, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate;
- wherein the product is free of nicotine, caffeine, and menthyl valerate.
A pharmaceutical composition to inhibit activation of the acetylcholine receptors in the central nervous system of a smoker during use of nicotine-containing products comprising:
- an effective amount of an active ingredient comprising at least one compound selected from the group consisting of camphor, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate;
- wherein the pharmaceutical composition is free of nicotine, caffeine, and menthyl valerate;
- and
- wherein the pharmaceutical composition further comprises a compound suitable for mediating transport across the blood-brain barrier.
A method for reducing an individual's desire to engage in smoking comprising:
- preparing a pharmaceutical composition, a portion thereof comprising an effective amount of an active ingredient;
- and
- administering the pharmaceutical composition to an individual, wherein the active ingredient comprises at least one compound selected from the group consisting of camphor, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate and wherein the product is free of nicotine, caffeine, and menthyl valerate.
A method for decreasing side-effects associated with smoking cessation comprising administering an effective amount of an active ingredient, wherein the active ingredient inhibits at least one of the receptors selected from the group consisting of nicotinic acetylcholine receptors and the TRPA1 channel.
A pharmaceutical composition for decreasing side-effects associated with smoking cessation comprising:
- a therapeutically effective amount of an active ingredient, wherein the active ingredient comprises an inhibitor of at least receptor selected from the group consisting of nicotinic acetylcholine receptors and the TRPA1 channel;
- wherein the pharmaceutical composition is free of nicotine, caffeine, and menthyl valerate.
Dependencies are inferred from the claim text.